How long do paxlovid side effects last

Pro Research Analysisby

Searched over 200M research papers

Analyzed relevant papers

Duration of Paxlovid Side Effects

Overview of Paxlovid Treatment

Paxlovid, an oral antiviral medication, has shown significant efficacy in reducing the severity of COVID-19 in patients at risk of serious illness. Clinical trials have demonstrated that Paxlovid can significantly lower hospitalization and mortality rates when administered within the first few days of symptom onset 13.

Common Side Effects of Paxlovid

While Paxlovid is generally well-tolerated, some side effects have been reported. These include gastrointestinal issues, such as diarrhea and nausea, as well as potential interactions with other medications. It is crucial for healthcare providers to monitor patients for renal and hepatic function during treatment due to the risk of drug interactions .

Duration of Side Effects

Short-Term Side Effects

Most side effects of Paxlovid are short-lived and tend to resolve within a few days after completing the treatment course. In a study involving children with hematological diseases, side effects such as fever, increased sleep, physical fatigue, and loss of appetite were observed within two weeks post-treatment . These side effects were generally mild and transient.

Long-Term Side Effects

There is limited evidence to suggest that Paxlovid causes long-term side effects. The majority of adverse reactions reported in clinical trials were mild and resolved shortly after the treatment period. No serious long-term side effects have been documented in the available studies 23.

Conclusion

Paxlovid is an effective treatment for reducing the severity of COVID-19, with most side effects being mild and short-lived. Patients typically experience side effects within the first few days of treatment, which generally resolve within two weeks. Continuous monitoring for drug interactions and organ function is recommended to ensure patient safety. Overall, Paxlovid's benefits in preventing severe COVID-19 outcomes outweigh the risks of its side effects.

Sources and full results

Most relevant research papers on this topic

Covid-19: Pfizer’s paxlovid is 89% effective in patients at risk of serious illness, company reports

Paxlovid is 89% effective in reducing hospital admissions and deaths in Covid-19 patients, with no deaths observed in the study.

RCTLarge Human TrialRigorous JournalHighly Cited

2021·

375citations

·Elisabeth Mahase

Clinical efficacy analysis of paxlovid in children with hematological diseases infected with the omicron SARS-CoV-2 new variant

Paxlovid is a safe and effective treatment for children 12 years old and younger with underlying hematological diseases infected with the new coronavirus, with no apparent adverse reactions.

Observational Study

2023·

4citations

·Yixian Li et al.

Safety and Efficacy of Paxlovid in COVID-19 Treatment: A Rapid Review

Paxlovid is an effective outpatient treatment for mild to moderate COVID-19 symptoms, but drug interactions remain uncertain.

Systematic Review

2022·

1citation

·M. Mobinizadeh et al.

Impact of extended-course oral nirmatrelvir/ritonavir (Paxlovid) in established Long COVID: Case series and research considerations

Long courses of oral nirmatrelvir/ritonavir may provide meaningful benefits for some people with Long COVID, but not others.

Case ReportPreprint

2023·

5citations

·Alison K. Cohen et al.

#5505 EFFICACY OF PAXLOVID WITHIN 5 DAYS VERSUS 5 DAYS AFTER DIAGNOSIS IN COVID-19 PATIENTS WITH CHRONIC KIDNEY DISEASE

Paxlovid is effective in COVID-19 patients with chronic kidney disease, but its use within 5 days of diagnosis is associated with more severe disease and increased use of glucocorticoids.

2023·

0citations

·Wenjuan Yu et al.

COVID-19 rebound after Paxlovid and Molnupiravir during January-June 2022

COVID-19 rebound occurred both after Paxlovid and Molnupiravir treatment, with higher rates in patients with underlying medical conditions.

Observational StudyHighly CitedPreprint

2022·

109citations

·Lindsey Wang et al.

Paxlovid-Induced Symptomatic Bradycardia and Syncope

Paxlovid, a COVID-19 treatment, may cause symptomatic bradycardia and syncope, and prompt discontinuation and intravenous atropine can help reverse these symptoms.

Case Report

2023·

10citations

·V. Ganipisetti et al.

The feasibility, safety, and efficacy of Paxlovid treatment in SARS-CoV-2-infected children aged 6–14 years: a cohort study

Paxlovid is a feasible option for treating SARS-CoV-2-infected children aged 6-14 years with underlying diseases, but further large-scale studies are needed to confirm its safety and efficacy.

Observational Study

2021·

37citations

·G. Yan et al.

Paxlovid reduces the risk of Long COVID in patients six months after hospital discharge

Paxlovid reduces the risk of Long COVID in high-risk patients six months after hospital discharge, improving their quality of life and reducing medical and economic burden.

Observational Study

2023·

14citations

·Yu Wang et al.

Hospitalization and Emergency Department Encounters for COVID-19 After Paxlovid Treatment - California, December 2021-May 2022.

Paxlovid treatment may prevent COVID-19-related hospitalizations in patients with mild to moderate COVID-19 at risk for progression to severe disease.

Observational StudyHighly Cited

2022·

70citations

·D. Malden et al.

Try another search

darkness science

current covid

bones for health

nebula in the night sky

magnesium and diarrhoea

mental health organization